Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation

Journal of Pediatric Surgery

Volumn 45, Issue 6, 2010, Pages 1080-1085

  Myers, Adrianne L ^a,b   Williams, Regan F ^a,b   Ng, Cathy Y ^a   Hartwich, Joseph E ^a,c   Davidoff, Andrew M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bevacizumab; Ionizing radiation; Rhabdomyosarcoma; VEGF inhibition

Indexed keywords

BEVACIZUMAB; ACTIN; CD34 ANTIGEN; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GROWTH INHIBITION; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; MALE; MATURITY; MICROVASCULATURE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; OXYGEN TENSION; PERICYTE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TISSUE OXYGENATION; TISSUE PERFUSION; TUMOR GROWTH; TUMOR XENOGRAFT; VASCULAR TUMOR; ADJUVANT THERAPY; ANGIOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD VESSEL; CAPILLARY PERMEABILITY; COMPARATIVE STUDY; DISEASE COURSE; DRUG EFFECTS; HUMAN; METABOLISM; MUSCLE NEOPLASMS; NEOPLASMS, EXPERIMENTAL; OXYGEN CONSUMPTION; PATHOLOGY; PHYSIOLOGY; RADIATION RESPONSE; RHABDOMYOSARCOMA, ALVEOLAR; SCID MOUSE; TOXICITY; VASCULARIZATION; XENOGRAFT;

ACTINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD34; BLOOD VESSELS; CAPILLARY PERMEABILITY; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; MUSCLE NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PHYSIOLOGIC; OXYGEN CONSUMPTION; RADIATION, IONIZING; RADIOTHERAPY, ADJUVANT; RHABDOMYOSARCOMA, ALVEOLAR; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953856505     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2010.02.068     Document Type: Article

References (12)

1. Loeb D.M., Thornton K., and Shokek O. Pediatric soft tissue sarcomas. Surg Clin N Am 88 (2008) 615-627
2. Wexler L.H., Meyer W.H., and Helman L.J. Rhabdomyosarcoma and the undifferentiated sarcomas. In: Pizzo P.A., and Poplack D.G. (Eds). Principles and practice of pediatric oncology. 5th ed (2006), Lippincott Williams & Wilkins, Philadelphia (Pa) 971-1001
3. Meza J.L., Anderson J., Pappo A.S., et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IV: the Children's Oncology Group. J Clin Oncol 24 (2006) 3844-3851
4. Raney R.B., Maurer H.M., Anderson J.R., et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 5 (2001) 9-15
5. Duda D.G., Batchelor T.T., Willett C.G., et al. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 13 (2007) 223-230
6. Gee M.F.W., Tsuchida R., Eichler-Jonsson C., et al. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 24 (2005) 8025-8037
7. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
8. Dickson P.V., Hamner J.B., Sims T.L., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13 (2007) 3942-3950
9. Spurbeck W.W., Ng C.Y., Strom T.S., et al. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 100 (2002) 3361-3368
10. Farrell C., Stewart P., and Del Maestro R. A new glioma model in rat: the C6 spheroid implantation technique permeability and vascular characterization. J Neuro-oncol 4 (1987) 403-415
11. Senger D.R., Galli S.J., Dvorak A.M., et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
12. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7 (2001) 987-989